<!DOCTYPE html>
<html>
<head>
  <!-- Site made with Mobirise Website Builder v3.11.1, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v3.11.1, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="shortcut icon" href="assets/images/logo.png" type="image/x-icon">
  <meta name="description" content="Website Builder Description">
  <title>Website Builder Title</title>
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lora:400,700,400italic,700italic&amp;subset=latin">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Raleway:100,100i,200,200i,300,300i,400,400i,500,500i,600,600i,700,700i,800,800i,900,900i">
  <link rel="stylesheet" href="assets/bootstrap-material-design-font/css/material.css">
  <link rel="stylesheet" href="assets/tether/tether.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/soundcloud-plugin/style.css">
  <link rel="stylesheet" href="assets/dropdown/css/style.css">
  <link rel="stylesheet" href="assets/animate.css/animate.min.css">
  <link rel="stylesheet" href="assets/theme/css/style.css">
  <link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
</head>
<body>
<section id="menu-3d">

    <nav class="navbar navbar-dropdown bg-color transparent">
        <div class="container">

            <div class="mbr-table">
                
                <div class="mbr-table-cell">

                    <button class="navbar-toggler pull-xs-right hidden-md-up" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="hamburger-icon"></div>
                    </button>

                    <ul class="nav-dropdown collapse pull-xs-right nav navbar-nav navbar-toggleable-sm" id="exCollapsingNavbar"><li class="nav-item"><a class="nav-link link" href="index.html">HOME&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Introduction.html">OVERVIEW&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Programme.html">PROGRAMME&nbsp;</a></li></ul>
                    <button hidden="" class="navbar-toggler navbar-close" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="close-icon"></div>
                    </button>

                </div>
            </div>

        </div>
    </nav>

</section>

<section class="engine"><a rel="external" href="https://mobirise.com">https://mobirise.com/</a></section><section class="mbr-section article mbr-section__container mbr-after-navbar" id="content1-3e" style="background-color: rgb(255, 255, 255); padding-top: 120px; padding-bottom: 0px;">

    <div class="container">
        <div class="row">
            <div class="col-xs-12 lead"><p><strong>Targeting the BACH1-NRF2 axis</strong></p><p><br></p><p>Laureano de la Vega</p><p><br></p><p>Division of Cellular Medicine, University of Dundee, UK.</p><p><strong>Email: </strong>l.delavega@dundee.ac.uk</p><p><strong><br></strong></p><p>NRF2 is a transcription factor that controls a wide variety of genes encoding for antioxidant, detoxification and anti-inflammatory proteins. Although the main negative regulator of the NRF2 pathway is KEAP1, there are additional factors that also negatively regulate the pathway. One of those factors is BACH1 (broad complex, tramtrack and bric à brac and cap’n’collar homology 1), a transcription factor that competes with NRF2 for its binding to the promoter of a subset of NRF2 target genes, being the potent antioxidant and anti-inflammatory enzyme HMOX1 the best characterised1. While KEAP1 inhibitors induce the expression of numerous cytoprotective genes, BACH1 inhibition will activate only a few, although they are extremely potent at inducing HMOX1. Additionally, BACH1 also activates genes involved in cancer metastasis (in a NRF2-independent manner)2. Based on this, BACH1 is a potential target against a variety of conditions linked to oxidative stress and inflammation, and also against cancer metastasis. Despite their therapeutic potential, only a few BACH1 inhibitors have been identified so far, and none has entered the clinical scenario yet.</p><p><span style="font-size: 1.07rem; line-height: 1.5;">In this talk I will provide new data comparing the use of HMOX1 as a reporter for NRF2 activation or as a reporter for BACH1 inhibition. I will explain the cellular model we use to identify BACH1 inhibitors and finally, I will present some recent data on the characterisation of novel potent dual KEAP1/BACH1 inhibitors and some of their potential use.</span><br></p><p><br></p><p><em>1. J. Sun et al., ‘Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene’, EMBO J., vol. 21, no. 19, pp. 5216–5224, Oct. 2002.&nbsp;</em></p><p><em>2. L. Lignitto et al., ‘Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1’, Cell, vol. 178, no. 2, pp. 316-329.e18, Jul. 2019</em></p><p><br></p></div>
        </div>
    </div>

</section>

<section class="mbr-section" id="msg-box5-3f" style="background-color: rgb(255, 255, 255); padding-top: 0px; padding-bottom: 0px;">

    
    <div class="container">
        <div class="row">
            <div class="mbr-table-md-up">

              <div class="mbr-table-cell mbr-right-padding-md-up mbr-valign-top col-md-7 image-size" style="width: 27%;">
                  <div class="mbr-figure"><img src="assets/images/laureano-de-la-vega-1400x1866.jpg"></div>
              </div>

              


              <div class="mbr-table-cell col-md-5 text-xs-center text-md-left content-size">
                  
                  <div class="lead">

                    <p><strong> Laureano de la Vega</strong> is a Senior Lecturer at the University of Dundee (UK). He is focused on the regulation of stress response pathways in health and disease, with special interest in cancer and neurodegenerative diseases. He is interested not only on the regulation of key master regulators of stress responses (i.e. NRF2, BACH1 or HSF1) but as well in the identification of novel pharmacological approaches to target these pathways.  </p>

                  </div>

                  
              </div>


              

            </div>
        </div>
    </div>

</section>


  <script src="assets/web/assets/jquery/jquery.min.js"></script>
  <script src="assets/tether/tether.min.js"></script>
  <script src="assets/bootstrap/js/bootstrap.min.js"></script>
  <script src="assets/smooth-scroll/SmoothScroll.js"></script>
  <script src="assets/dropdown/js/script.min.js"></script>
  <script src="assets/touchSwipe/jquery.touchSwipe.min.js"></script>
  <script src="assets/viewportChecker/jquery.viewportchecker.js"></script>
  <script src="assets/theme/js/script.js"></script>
  
  
  <input name="animation" type="hidden">
  </body>
</html>